ClinicalTrials.gg

Program

lisocabtagene maraleucel

Also written as “Liso-cel”, “JCAR017” and “JCAR017 (lisocabtagene maraleucel)”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.

Furthest: phase 3, since Dec 19, 202310 company-led studies, 3 open or runningNext primary completion: Nov 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb103 open or runningphase 3since Dec 19, 2023Dec 11, 2015Nov 26, 2027phase 2 · NCT03331198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2015First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT02631044 · 387 enrolled · United States
  2. Oct 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198 · 320 enrolled · United States, Canada
  3. Mar 23, 20182 phase 2 studies in Lymphoma, Non-HodgkinNCT03483103, NCT03484702
  4. Oct 18, 2018Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03743246 · 21 enrolled · United States, France, Germany and more
  5. Nov 7, 2018Phase 2 study in Lymphoma, Non-HodgkinNCT03744676 · 104 enrolled · United States
  6. Jan 27, 2020Phase 2 study in Lymphoma, Non-HodgkinNCT04245839 · 276 enrolled · United States, Austria, Canada and more
  7. Dec 19, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06205290 · United States, Austria, Belgium and more
  8. Feb 26, 2024Phase 3 study in RecurrenceNCT06313996
  9. Jun 3, 2025Phase 2 study in LymphomaNCT07015242 · 65 planned · United States, France, Germany

Ahead

  1. Nov 26, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198
  2. Jan 9, 2028Primary completion: phase 2 study in LymphomaNCT07015242
  3. Sep 30, 2031Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT04245839

TargetBeta

CD19 →read by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07015242Lymphoma · United States, France, Germany2RecruitingJan 9, 202865
NCT06313996Recurrence3WithdrawnOct 16, 20310
NCT06205290Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more3WithdrawnOct 13, 20310
NCT04245839Lymphoma, Non-Hodgkin · United States, Austria, Canada and more2Active, not recruitingSep 30, 2031276
NCT03744676Lymphoma, Non-Hodgkin · United States2CompletedSep 22, 2023104
NCT03743246Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more2TerminatedJan 26, 202421
NCT03484702Lymphoma, Non-Hodgkin · Austria, Belgium, Finland and more2CompletedDec 15, 2023113
NCT03483103Lymphoma, Non-Hodgkin · United States2CompletedSep 24, 202174
NCT03331198Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada2Active, not recruitingNov 26, 2027320
NCT02631044Lymphoma, Non-Hodgkin · United States1CompletedMay 16, 2024387

How it is read

Names in the registry

  • “Liso-cel”, 3 entries
  • “JCAR017”, 3 entries
  • “lisocabtagene maraleucel”, 2 entries
  • “JCAR017 (lisocabtagene maraleucel)”, 1 entry
  • “JCAR017 (lisocabtagene maraleucel) + ibrutinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.